Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.630.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- MET Receptor Tyrosine Kinase
- c-Met Receptor Tyrosine Kinase
- c Met Receptor Tyrosine Kinase
- Receptor, Hepatocyte Growth Factor
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
- Scatter Factor Receptor
- Receptor, HGF
- HGF Receptor
- Hepatocyte Growth Factor Receptor
- c-met Proteins
- c met Proteins
- MET Proto-Oncogene, Receptor Tyrosine Kinase
- MET Proto Oncogene, Receptor Tyrosine Kinase
- Receptor, Scatter Factor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 2 | 3 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 4 | 4 | 8 |
| 2008 | 1 | 4 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 1 | 8 |
| 2011 | 5 | 2 | 7 |
| 2012 | 8 | 2 | 10 |
| 2013 | 8 | 3 | 11 |
| 2014 | 12 | 3 | 15 |
| 2015 | 9 | 7 | 16 |
| 2016 | 8 | 5 | 13 |
| 2017 | 8 | 3 | 11 |
| 2018 | 7 | 3 | 10 |
| 2019 | 5 | 0 | 5 |
| 2020 | 4 | 3 | 7 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer. Cancer Lett. 2024 Apr 28; 588:216780.
-
EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma. Cancer Biomark. 2024; 39(4):289-298.
-
MET Gene High Copy Number (Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy. Am J Clin Pathol. 2022 04 01; 157(4):502-505.
-
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol. 2021; 5.
-
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung?cancer. ESMO Open. 2021 12; 6(6):100319.
-
Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. J Cell Mol Med. 2021 11; 25(21):10164-10174.
-
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
-
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
-
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2021 10; 88(4):643-654.